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Abstract
While both the 2012 and 2014 Consumer Reports concerned arsenic levels in US rice, no previous 
study has evaluated long-term consumption of total rice, white rice and brown rice in relation to 
risk of developing cancers. We investigated this in the female Nurses' Health Study (1984-2010), 
and Nurses' Health Study II (1989-2009), and the male Health Professionals Follow-up Study 
(1986-2008), which included a total of 45,231 men and 160,408 women, free of cancer at baseline. 
Validated food frequency questionnaires were used to measure rice consumption at baseline and 
repeated almost every 4 years thereafter. We employed Cox proportional hazards regression model 
to estimate multivariable relative risks (RRs) and 95% confidence intervals (95% CIs). During up 
to 26 years of follow-up, we documented 31,655 incident cancer cases (10,833 in men and 20,822 
in women). Age-adjusted results were similar to multivariable-adjusted results. Compared to 
participants with less than one serving per week, the multivariable RRs of overall cancer for 
individuals who ate at least 5 servings per week were 0.97 for total rice (95% CI: 0.85-1.07), 0.87 
for white rice (95% CI: 0.75-1.01), and 1.17 for brown rice (95% CI: 0.90-1.26). Similar non-
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significant associations were observed for specific sites of cancers including prostate, breast, colon 
and rectum, melanoma, bladder, kidney, and lung. Additionally, the null associations were 
observed among European Americans and non-smokers, and were not modified by BMI. Long-
term consumption of total rice, white rice or brown rice was not associated with risk of developing 
cancer in US men and women.
Keywords
rice; arsenic; prostate cancer; breast cancer; colorectal cancer; melanoma; bladder cancer; kidney 
cancer; lung cancer
 Introduction
Paddy rice is a major component of the global food supply, serving as a staple for over 50% 
of the world population 1. Compared to Asian countries, per capita rice consumption in the 
US is much lower with substantial variation across ethnic groups2. White rice, as milled 
grain with husk, bran and germ removed, has a finer texture and longer shelf life. In contrast, 
brown rice is a whole grain, produced by only removing the outermost layer (husk) and thus 
contains more dietary fiber, minerals, and biologically active substances3-6.
Both the 2012 and 2014 Consumer Reports claimed that “samples of white rice, brown rice 
and rice breakfast cereals that many U.S. adults and children eat may contain worrisome 
levels of arsenic”7. While arsenic is a naturally occurring element found in air, soil, water, 
and foods, inorganic arsenic has been linked with various types of cancers, including those 
of the lung, liver, bladder, kidney and skin8-12. Nonetheless, it remains unclear whether 
arsenic intakes at the levels found in rice are related to risk of human cancer.
Hence, we conducted this first study to comprehensively evaluate whether individuals with 
relatively high amounts of rice consumption over decades have a higher risk of developing 
cancers. Specifically, we utilized unique data from three well-established on-going 
prospective cohorts, the female Nurses’ Health Study and Nurses’ Health Study II, and the 
male Health Professionals Follow-up Study. In each cohort we have collected detailed 
information on consumption of white rice and brown rice every 4 years for up to 26 years.
 Materials and Methods
 Study population
We used the data from three on-going prospective US cohorts: the Nurses' Health Study 
(NHS, n = 121,700 registered female nurses, aged 30 to 55 years at baseline in 1976), the 
Nurses’ Health Study II (NHS II, n = 116,609 registered female nurses, aged 25 to 42 at 
baseline in 1989), and the Health Professionals Follow-up Study (HPFS, n = 51,529 male 
professionals, aged 40 to 75 years at baseline in 1986). Details of these three cohorts have 
been described elsewhere 13-15. In all three cohorts, participants at enrollment completed 
baseline questionnaires regarding lifestyle, diet and newly diagnosed diseases. During the 
follow-up questionnaires were administered every 2 years to update medical, lifestyle and 
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other health-related information. The follow-up rate has been greater than 90% for each 
cohort.
In the current analysis, we excluded participants with diagnosis of cancer at baseline and 
those with missing date of cancer diagnosis. In addition, we excluded participants with 
missing information on rice consumption at baseline, those with unusual self-reported total 
energy intake (i.e. < 500 or > 3500 kcal/day for NHS and NHS II; < 800 or > 4200 kcal/day 
for HPFS). After exclusion, data from 70,144 (of 81,755) NHS participants, 90,264 (of 
95,452) NHS II participants, and 45,231 (of 51,530) HPFS participants were available for 
the analysis.
These cohorts have been approved by the institutional review boards at the Harvard School 
of Pubic Heath and Brigham and Women’s Hospital, Boston, Massachusetts. The 
completion of the self-administered questionnaire was considered to imply informed 
consent..
 Assessment of rice consumption
Information on rice consumption was first assessed in 1980 in NHS participants using a 
validated semi-quantitative food frequency questionnaire (SFFQ), and repeated in 1984, 
1986, and every 4 years thereafter. Similar SFFQs were administered every 4 years for NHS 
II participants during 1991 through 2009 and for HPFS participants during 1986 through 
2008. In each SFFQ, we asked the participants how often, on average over the past year, they 
consumed a specified portion size of each food, with nine possible frequency choices 
ranging from “almost never” to “6 or more times per day”. For white rice and brown rice, we 
used 1 cup as the serving unit. The total rice intake was calculated as the sum of white rice 
and brown rice. In the current study, we categorized participants’ rice intake into 4 
categories (< 1 serving per week, 1 serving per week, 2-4 servings per week and ≥ 5 
servings per week). The reproducibility and validity of these SFFQs have been evaluated in 
detail elsewhere16-19. Assessments of white rice and brown rice consumption were 
moderately correlated with diet record assessments. For example, the corrected Pearson 
correlation coefficients between these 2 assessments were 0.53 for white rice and 0.41 for 
brown rice in the HPFS 16.
 Assessment of other covariates
Other dietary factors such as consumption of red meat, fish, alcohol, fruit and vegetables, 
whole grain, nuts were also collected from the baseline and subsequent SFFQs. Nutrient 
intakes were calculated as the frequency of intake multiplied by the nutrient composition of 
the specified portion size; the composition values were obtained mainly from U.S. 
Department of Agriculture sources, supplemented with other data. In addition, we also 
collected and updated information on medical, lifestyle and other health-related factors, such 
as body weight, physical activity, smoking status, family history of cancer, multivitamin use, 
and history of diabetes, hypertension and hypercholesterolemia. In NHS and NHS II, we 
also queried postmenopausal hormone use.
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 Ascertainment of incident cancer cases
In each cohort, participants reported cancer and other disease endpoints in biennial 
questionnaires. Researchers obtained permission from the study participants to obtain their 
medical records and pathological reports and abstracted the information on anatomic 
location, stage, and histological type of the cancer. The confirmed cancers were defined 
according to the International Classification of Diseases, Ninth Revision [ICD-9]20.
 Statistical analysis
We computed person-time of follow-up for each participant from the return date of the 
baseline questionnaire to the date of cancer diagnosis, death from any cause, or the end of 
follow-up (May 31st, 2010 in NHS, May 31st, 2009 in NHS II, and January 31st, 2008 in 
HPFS), whichever came first. Relative risks (RRs) and 95% confidence intervals (CI’s) of 
total and site-specific cancers were estimated using time-dependent Cox proportional 
hazards regression models 21. All models were stratified by age in months and calendar 
time. In multivariate analysis, we simultaneously controlled for ethnicity and other factors 
that may influence cancer risk (see Table 2 footnote for these variables and their 
categorizations). In NHS and NHS II, we further adjusted for postmenopausal hormone use 
(never, past, current). To better represent long-term diet and minimize the effect of within-
person variation, we used the cumulative average intake method 22. Specifically we 
calculated the cumulative average from all SFFQs until the diagnosis of cancer, death, or the 
end of follow-up. To address the missing dietary information in repeated SFFQs, we 
replaced the missing values of dietary variables with those from the previous SFFQ.
In addition to overall cancer, we further investigated the risk of common site-specific 
cancers, including prostate cancer, breast cancer, lung cancer, colorectal cancer, bladder 
cancer, kidney cancer and melanoma. In NHS II, only breast cancer and melanoma were 
included in the site-specific analysis due to the small number of cases for other cancers. We 
also conducted several sensitivity analyses: (1) for total rice consumption, we examined 
intake of at least 1 serving/day; (2) in men, we also excluded the cases of organ-confined 
prostate cancer, as those were usually detected from PSA screening test and had high 
incidence but good prognosis; (3) we applied 4 to 8 years lag due to concern of reverse 
causation because participants with subclinical malignancy may change their diet due to the 
illness; (4) we further examined whether the associations were modified by ethnicity, 
smoking status, and body mass index (BMI). In our 3 cohorts, the majority of participants 
are European Americans, and we were unable to have stable estimate in other ethnicity due 
to small sample size. Therefore, we restricted the stratified analysis to European Americans . 
Similarly we conducted analyses stratified by smoking status (never, past, and current) and 
by BMI (< 25, 25-30, and ≥ 30 kg/m2).
Tests for trend were conducted by assigning the median value to each category and using 
this variable as a continuous variable in the models. We used the meta-analysis assuming 
fixed-effects to pool the RRs from multivariate models across the 3 cohorts. P values for 
heterogeneity between cohorts were calculated by Cochran Q test 23. All P values were 2-
sided and all statistical procedures were performed using SAS release 9.2 (SAS Institute, 
Cary, NC)
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 Results
We identified 15,673 incident cancer cases during 26 years of follow-up in the NHS, 5,149 
cases during 18 years in the NHS II, and 10,833 cases during 22 years in the HPFS. In NHS, 
breast cancer was the most common cancer (n = 5,714; 36.8%), followed by colorectal 
cancer (n = 1,352; 8.7%) and lung cancer (n = 1,205; 7.7%). In NHS II, breast cancer was 
the most common cancer (n = 2,401; 47.0%) and melanoma was the next common cancer (n 
= 538; 10.4%). In HPFS, prostate cancer was the most common cancer (n = 5,060; 46.7%), 
followed by colorectal cancer (n = 1,042; 9.6%) and lung cancer (n = 742; 6.8%).
Baseline characteristics of the study participants according to the intake of white rice and 
brown rice are shown in table 1. In men and women, Asian participants were more likely to 
have higher white rice intake. Ethnicity was not strongly associated with brown rice intake. 
However, higher brown rice consumption in general was expectedly associated with more 
health-conscious diet and lifestyles variables, including greater level of physical activity, less 
cigarette smoking, more use of multivitamin supplement, and higher intake of fruit, 
vegetables and whole grain.
As shown in Table 2, long-term total rice intake was not associated with risk of overall 
cancer incidence. Specifically, participants who ate at least 5 servings of total rice per week 
had a relative risk of 0.97 (95% CI 0.85-1.07; P for trend 0.37). Similarly, neither white rice 
intake (Table 3) nor brown rice intake (Table 4) was associated with overall cancer risk. For 
the same comparison, the multivariable RRs of overall cancer risk were 0.87 for white rice 
(95% CI 0.75-1.01; P for trend 0.17) and 1.07 for brown rice (95% CI 0.90-1.26; P for trend 
0.97).
In terms of the specific cancer sites, total rice consumption was not associated with risk of 
prostate, colorectal, lung, kidney cancer in any of these cohorts separately or pooled 
analyses (Table 5). For bladder cancer, borderline significant positive associations were seen 
with intake of total rice in both NHS and HPFS (pooled RR = 1.32, 95% CI 0.99-1.76; P for 
trend 0.09). For prostate cancer, the results did not change materially after excluding 
participants diagnosed with organ-confined tumor (RR for total rice consumption ≥ 5 vs. < 1 
servings/wk: 1.06; 95% CI: 0.79-1.42; P for trend 0.76).
In the sensitivity analyses, we found similar results after restricting our analyses within 
European Americans, never smokers, applying 4 to 8 years lag in updating dietary intakes, 
or stratified analyses according to BMI (Supplemental table 1). In addition, rice 
consumption was not associated with risk of bladder cancer by smoking status or breast 
cancer by menopausal status (Supplemental table 2).
 Discussion
During up 18 to 26 years follow-up for over 280,000 US men and women, results from 3 
prospective cohorts suggested the intakes of total rice, white rice or brown rice were not 
significantly associated with the risk of overall cancers. The null association remained 
among European American participants, never smokers, and after stratifying by BMI.
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While arsenic and inorganic arsenic are carcinogenic to humans, it remains unknown 
whether arsenic associated with rice consumption increases risks of developing cancers. 
Hence, we conducted this first study to specifically address the question whether amounts of 
arsenic in rice are sufficient to see a detectable increase in cancer risk. Our study found no 
association between long-term rice consumption and overall cancer risk. To our knowledge, 
this study is the only analysis to date to assess the associations between the rice consumption 
and the risk of overall cancers. The age-adjusted null results were essentially similar to 
multivariable results. Additionally, the null results were observed in both genders and even 
among individuals with regular intake for decades. The highest category of rice intake in our 
study was at least 5 servings per week, which is approximately equivalent to 9.5μg/day 
inorganic arsenic from white rice, or 20.1μg/day from brown rice (1 serving = 1 cup ≈ 158 g 
cooked white rice or 195 g cooked brown rice 40). These amounts of arsenic in our study 
were comparable with those based on the Consumer Reports, which have shown that the 
average inorganic arsenic level is 13.3μg/cup in white rice and 28.2μg/cup in brown rice 7).
With regard to cancer sites, our study did not observe a statistically significant association 
between rice consumption and risk of any each specific cancer. However, it worthwhile 
noting that we observed a borderline significant increased risk of bladder cancer comparing 
≥ 5/week vs. <1 week of total rice intake (RR= 1.32, 95% CI: 0.99, 1.76). While we did not 
directly measure arsenic in this study, bladder cancer is arguably the most susceptible cancer 
site to arsenic exposure although studies on bladder cancer and arsenic in low concentrations 
have been inconsistent 41,42. Clearly, our observation of borderline significant associations 
between rice intake and bladder cancer risk clearly warrants further investigation.
Strengths of our study include the large population, prospective design with decades of 
follow-up, repeated assessments of rice consumption, parallel analyses among men and 
women, and control for many risk factors for cancers. Limitations of this study merit 
consideration. First, our study did not directly measure arsenic levels in rice or other foods. 
Instead, this study addressed the specific question of whether the amounts of arsenic in rice 
are sufficient to see a detectable increase in cancer risk. We acknowledge that studies of 
arsenic are clearly desirable, but possibly require a biomarker. Second, measurement errors 
using SFFQs to assess rice intake exist. However, the correlations (r~0.5) between the 
SFFQs and multiple 1-week dietary records suggested that rice consumption was reasonably 
assessed in current study. Thirdly, our results should be generalized to other population with 
caution because most of our study participants are of European origin. The rice products 
consumed by our European-American participants were much less than those eaten by 
Asian, Hispanic and Indian populations. In addition, we have no information on where the 
rice was produced in the US, and arsenic levels in rice may vary by place of production, rice 
cooking methods, and the quality of water used to cook rice. Fourthly, as with all 
observational studies, residual confounding by other factors cannot be totally excluded; 
however, the consistently observed null results in both men and women argued against 
missing strong associations. Lastly, while our sample sizes are large overall, we had limited 
power to examine the potential effect of rice consumption on certain cancer sites with 
relatively low incidence in the US.
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In summary, we did not find statistically significant associations between rice consumption 
and overall cancer risk in adult men or women. Future research to combine measuring levels 
of arsenic with amounts of rice consumption is warranted to better evaluate the effect of 
arsenic ingested from food on cancer risk.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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BRIEF DESCRIPTION OF NOVELTY AND IMPACT OF PAPER
We conducted the first study to comprehensively examine the associations between 
consumption of total rice, white rice and brown rice and risk of developing cancers. 
Results from this study suggest that long-term consumption of total rice, white rice or 
brown rice was not associated with risk of developing cancers in US men and women. 
Future research to combine measuring levels of arsenic with amounts of rice 
consumption is warranted.
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Table 1
Baseline Age-Standardized Characteristics According to White Rice and Brown Rice Intake
White Rice Intake Brown Rice Intake
< 1/wk 1/wk 2-4/wk ≥ 5/wk < 1/wk 1/wk 2-4/wk ≥ 5/wk
NHS
Participants, No. 47,461 5,126 640 4,461 1,291 198
Age, y 50.8 49.5 49.5 50.2 50.3 50.5 51.1 51.6
Rice intake, servings/d 0.047 0.14 0.43 1.04 0.013 0.14 0.43 0.99
Physical activity, MET-h/wk 13.8 14.2 15.1 15.7 13.5 19.0 22.1
BMI, km2 25.1 25.0 24.9 24.4 25.1 24.6 24.3 23.7
Race, %
 European Americans 98.8 .1 93.7 50.9 97.9 98.1 96.4 92.6
 Asian 0.16 0.25 1.6 41.9 0.7 0.3 1.0 2.6
 African-American 0.33 0.62 1.6 1.6 1.0 0.9 1.9 2.5
 Other 0.72 1.08 3.1 5.7 0.5 0.7 0.8 2.3
Never smoking, % 43.9 43.1 44.5 56.3 43.8 43.6 45.2 53.4
Type 2 diabetes, % 3.2 3.1 3.3 4.9 3.2 2.9 3.0 3.6
Current multivitamin use, % 36.9 36.2 37.4 37.2 35.8 46.3 52.2 48.1
Dietary intake
 Alcohol, g/d 6.5 7.5 8.1 3.9 6.8 7.5 6.8 5.1
 Fruit, servings/d 2.0 2.2 2.3 2.5 2.1 2.6 2.9 3.0
 Vegetables, servings/d 2.4 2.7 3.0 2.9 2.4 3.1 3.5 4.0
 Red meat, servings/d 1.2 1.3 1.3 1.4 1.3 1.1 1.0 0.7
 Fish, servings/d 0.2 0.2 0.3 0.3 0.2 0.3 0.3 0.3
 Whole grain, g/d 14.4 13.3 13.1 10.4 12.9 22.2 37.0 66.7
NHS II
Participants, No. 50,134 26,436 11,727 1,967 74,030 11,406 4,201 627
Age, y 35.9 36.3 36.4 36.3 36.1 36 36.2 36.6
Rice intake, servings/d 0.045 0.14 0.43 1.14 0.019 0.14 0.43 0.93
Physical activity, MET-h/wk 20.6 20.6 22.1 21.3 19.4 26 28.9 38.6
BMI, kg/m2 24.7 24.6 24.6 24 24.7 24.1 24.0 24.0
 Race, %
 European Americans 94.5 94.1 89.2 50.9 92.5 94.6 92.8 85.8
 Asian 0.4 0.8 2.5 37.0 1.7 0.8 0.9 4.2
 African-American 1.2 1.3 2.5 4.1 1.6 0.9 1.2 4.0
 Other 3.9 3.9 5.8 8.0 4.2 3.7 5.1 6.0
Never smoking, % 65.7 65.3 65.1 74.5 66.2 63.9 61.5 61.6
Type 2 diabetes, % 1.0 1.0 0.9 1.0 1.0 0.8 0.9 1.2
Current multivitamin use, % 43.8 43.3 44.9 43.7 42.5 48.9 51.0 52.5
Dietary intake
 Alcohol, g/d 2.9 3.3 3.5 2.4 3.0 3.7 3.8 3.1
 Fruit, servings/d 1.1 1.3 1.4 1.4 1.1 1.5 1.7 2.0
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White Rice Intake Brown Rice Intake
< 1/wk 1/wk 2-4/wk ≥ 5/wk < 1/wk 1/wk 2-4/wk ≥ 5/wk
 Vegetables, servings/d 3.0 3.5 4.0 4.3 3.1 4.0 4.8 6.1
 Red meat, servings/d 0.8 0.8 0.8 0.8 0.8 0.7 0.6 0.5
 Fish, servings/d 0.2 0.3 0.3 0.4 0.3 0.3 0.4 0.4
 Whole grain, g/d 20.8 20.1 20.2 16.4 17.7 27.3 43.4 66.8
HPFS
Participants, No. 28,432 11,295 4,748 907 36,917 5,966 2,131 368
Age, y 54.6 52.2 52.1 51.7 54.1 51.7 52.3 52.5
Rice intake, servings/d 0.04 0.14 0.43 1.06 0.02 0.41 0.43 0.98
Physical activity, MET-h/wk 20.8 21.6 21.0 20.3 20.0 24.4 26.8 33.3
BMI, kg/m2 25.0 25.0 24.8 24.2 25.0 24.8 24.5 23.7
Race, %
 European Americans 96.7 96.0 91.0 48.5 95.0 96.1 94.3 83.4
 Asian 0.3 0.5 3.9 46.1 1.7 0.6 1.6 12.9
 African-American 0.7 1.0 2.6 2.2 1.0 0.9 1.6 1.1
 Other 2.2 2.5 2.5 3.2 2.3 2.4 2.5 2.6
Never smoking, % 44.7 45.6 43.9 45.0 44.1 47.9 48.8 49.2
Type 2 diabetes, % 3.0 3.2 3.4 4.3 3.1 3.1 3.2 2.8
Current multivitamin use, % 42.3 40.3 40.5 45.2 40.4 45.6 50.4 52.2
Dietary intake
 Alcohol, g/d 11.3 11.6 11.5 8.4 11.3 11.5 11.0 8.3
 Fruit, servings/d 2.3 2.5 2.6 2.5 2.2 2.8 3.1 3.6
 Vegetables, servings/d 2.9 3.3 3.7 3.4 2.9 3.7 4.3 5.1
 Red meat, servings/d 1.1 1.2 1.2 1.2 1.2 1.0 0.9 0.5
 Fish, servings/d 0.3 0.4 0.4 0.4 0.3 0.4 0.5 0.6
 Whole grain, g/d 22.3 21.8 21.9 18.2 19.1 28.5 45.2 76.9
Values are means or percentages and are standardized to the age distribution of the study population except for the age variable; MET-h hours of 
metabolic equivalent tasks; BMI = body mass index.
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Table 2
Risk of Overall Cancer According to Total Rice Intake in the HPFS, NHS I, nad NHS II
White Rice Intake, No. of Servings
< 1/week 1/week 2-4/week ≥ 5/week p-value
NHS
 No. of cases 6,931 3,442 4,776 524
 RR (95% CI)
  Model 1a 1 (ref) 1.00 (0.96, 1.04) 0.98 (0.94, 1.01) 0.94 (0.86, 1.02) 0.08
  Model 2b 1 (ref) 1.01 (0.97, 1.05) 1.00 (0.96, 1.04) 1.02 (0.93, 1.12) 0.81
  Model 3c 1 (ref) 1.01 (0.97, 1.05) 1.00 (0.96, 1.04) 1.02 (0.93, 1.12) 0.72
NHS II
 No. of cases 1,693 1,165 1,904 387
 RR (95% CI)
  Model 1a 1 (ref) 0.94 (0.87, 1.01) 0.95 (0.89, 1.02) 0.82 (0.73, 0.92) 0.001
  Model 2b 1 (ref) 0.92 (0.86, 1.00) 0.92 (0.86, 0.98) 0.82 (0.73, 0.92) 0.001
  Model 3c 1 (ref) 0.93 (0.86, 1.00) 0.93 (0.86, 0.99) 0.83 (0.73, 0.94) 0.003
HPFS
 No. of cases 3,920 2,290 3,751 872
 RR (95% CI)
  Model 1a 1 (ref) 0.98 (0.93, 1.03) 0.99 (0.95, 1.04) 0.94 (0.87, 1.01) 0.14
  Model 2b 1 (ref) 0.99 (0.94, 1.04) 1.00 (0.95, 1.04) 1.00 (0.92, 1.08) 0.99
  Model 3c 1 (ref) 0.99 (0.94, 1.04) 1.00 (0.95, 1.05) 1.00 (0.93, 1.10) 0.85
Pooled results
 RR (95% CI) 1 (ref) 0.98 (0.93, 1.03) 0.98 (0.94, 1.02) 0.97 (0.85, 1.07) 0.37
 P heterogeneity 0.07 0.10 0.02 0.02
Abbreviation: C I, confidence interval; HPFS, Health Professionals Follow-up Study; NHS, Nurses’ Health Study
aAge-adjusted.
bAdjusted for age (years), ethnicity (European Americans, Asian, African American, other), body mass index (calculated as weight in kilograms 
divided by height in meters squared; <21.0, 21.0-22,9, 23.0-24.9, 25.0.26.9, 27.0-29.9, 30.0-32.9, or ≥ 35.0) smoking status (never smoked, past 
smokers, current smokers 1-14 cigarettes/day, 15-24 cigarettes/day, or ≥ 25 cigarettes/day), physical activity (MET-hours/week, in quintiles), family 
history of cancer (yes or no), multivitamin supplementation (yes or no), and total energy intake (kilocalories/day, in quintiles). For women, 
postmenopausal hormone use (yes or no) was further adjusted for.
c
In addition to model 2, model 3 was further adjusted for intake of alcohol, fruit, vegetables, red meat, fish, nuts, whole grain (except brown rice), 
sugar-sweetened beverage (all in quartiles).
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Table 3
Risk of Overall Cancer According to White Rice Intake in the HPFS, NHS I, and NHS II
White Rice Intake, No. of Servings
< 1/week 1/week 2-4/week ≥ 5/week p-value
NHS
 No. of cases 9,588 3,093 2,815 177
 RR (95% CI)
  Model 1a 1 (ref) 1.00 (0.96, 1.05) 1.01 (0.96, 1.05) 0.85 (0.74, 0.99) 0.20
  Model 2b 1 (ref) 1.01 (0.97, 1.05) 1.02 (0.98, 1.06) 0.96 (0.81, 1.14) 0.74
  Model 3c 1 (ref) 1.01 (0.96, 1.05) 1.02 (0.97, 1.06) 0.96 (0.81, 1.14) 0.80
NHS II
 No. of cases 2,636 1,210 1,196 107
 RR (95% CI)
  Model 1a 1 (ref) 0.96 (0.90, 1.03) 0.98 (0.92, 1.05) 0.70 (0.58, 0.85) 0.002
  Model 2b 1 (ref) 0.96 (0.89, 1.02) 0.96 (0.89, 1.02) 0.72 (0.58, 0.89) 0.004
  Model 3c 1 (ref) 0.96 (0.89, 1.03) 0.96 (0.90, 1.03) 0.73 (0.59, 0.90) 0.01
HPFS
 No. of cases 6,391 2,102 2,087 253
 RR (95% CI)
  Model 1a 1 (ref) 1.01 (0.96, 1.06) 1.03 (0.98, 1.08) 0.84 (0.74, 0.95) 0.09
  Model 2b 1 (ref) 1.02 (0.97, 1.07) 1.03 (0.98, 1.08) 0.92 (0.79, 1.06) 0.76
  Model 3c 1 (ref) 1.02 (0.97, 1.07) 1.03 (0.98, 1.08) 0.91 (0.79, 1.05) 0.70
Pooled results
 RR (95% CI) 1 (ref) 1.00 (0.97, 1.03) 1.01 (0.97, 1.04) 0.87 (0.75, 1.01) 0.17
 P heterogeneity 0.32 0.24 0.28 0.07
Abbreviation: CI, confidence interval; HPFS, Health Professionals Follow-up Study; NHS, Nurses’ Health Study
aAge-adjusted.
bAdjusted for the same sets of covariates as for model 2 and model 3 in table 2
cAdjusted for the same sets of covariates as for model 2 and model 3 in table 2
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Table 4
Risk of Overall Cance According to Brown Rice Intake in the HPFS, NHS I, and NHS II
Brown Rice Intake, No. of Servings
< 1/week 1/week 2-4/week ≥ 5/week p-value
NHS
 No. of cases 14,107 798 707 61
 RR (95% CI)
  Model 1a 1 (ref) 0.99 (0.92, 1.06) 0.95 (0.88, 1.03) 0.98 (0.76, 1.25) 0.25
  Model 2b 1 (ref) 1.01 (0.94, 1.09) 0.99 (0.92, 1.07) 1.05 (0.82, 1.36) 0.88
  Model 3c 1 (ref) 1.02 (0.95, 1.10) 1.00 (0.93, 1.09) 1.07 (0.84, 1.38) 0.69
NHS II
 No. of cases 4,233 478 388 50
 RR (95% CI)
  Model 1a 1 (ref) 1.01 (0.92, 1.11) 0.95 (0.85, 1.05) 1.20 (0.91, 1.59) 0.95
  Model 2b 1 (ref) 1.01 (0.92, 1.11) 0.93 (0.84, 1.03) 1.22 (0.92, 1.62) 0.88
  Model 3c 1 (ref) 1.02 (0.93, 1.13) 0.95 (0.85, 1.06) 1.28 (0.96, 1.70) 0.66
HPFS
 No. of cases 8,886 999 856 92
 RR (95% CI)
  Model 1a 1 (ref) 0.98 (0.92, 1.05) 0.95 (0.88, 1.01) 0.86 (0.70, 1.06) 0.04
  Model 2b 1 (ref) 1.00 (0.93, 1.06) 0.95 (0.89, 1.04) 0.93 (0.75, 1.14) 0.18
  Model 3c 1 (ref) 1.00 (0.94, 1.07) 0.96 (0.91, 1.05) 0.95 (0.77, 1.17) 0.36
Pooled results
 RR (95% CI) 1 (ref) 1.01 (0.97, 1.06) 0.98 (0.94, 1.03) 1.07 (0.90, 1.26) 0.97
 P heterogeneity 0.91 0.74 0.25 0.59
Abbreviation: CI, confidence interval; HPFS, Health Professionals Follow-up Study; NHS, Nurses’ Health Study
aAge-adjusted.
bAdjusted for the same sets of covariates as for model 2 and model 3 in table 2
cAdjusted for the same sets of covariates as for model 2 and model 3 in table 2
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Table 5
Risk of Specific Sites of Cancer According to Total Rice Intake in the HPFS, NHS I, and NHS II
Total Rice Intake, No. of Servings
No. < 1/week 1/week 2-4/week ≥ 5/week p-value
  Prostate
  HPFS 5,060 1 (ref) 1.03 (0.96, 1.11) 1.00 (0.93, 1.07) 1.02 (0.91, 1.15) 0.86
  Breast
  NHS 5,714 1 (ref) 0.97 (0.91, 1.04) 1.00 (0.94, 1.07) 1.03 (0.89, 1.20) 0.64
  NHS II 2,401 1 (ref) 0.91 (0.81, 1.02) 0.95 (0.85,1.05) 0.80 (0.67, 0.96) 0.04
  Pooled 1 (ref) 0.95 (0.88, 1.03) 0.99 (0.93, 1.04) 0.90 (0.70, 1.16) 0.48
  Colorectal
  NHS 1,352 1 (ref) 1.02 (0.89, 1.18) 1.02 (0.88, 1.16) 0.99 (0.71, 1.38) 0.96
  HPFS 1,042 1 (ref) 0.98 (0.83, 1.16) 1.09 (0.93, 1.27) 0.88 (0.66, 1.16) 0.51
  Pooled 1 (ref) 1.01 (0.91, 1.13) 1.04 (0.93, 1.15) 0.91 (0.74, 1.13) 0.57
  Melanoma
  NHS 870 1 (ref) 1.14 (0.97, 1.36) 1.00 (0.84, 1.18) 0.92 (0.60, 1.40) 0.63
  NHS II 538 1 (ref) 0.94 (0.74, 1.18) 0.90 (0.72, 1.12) 0.93 (0.65, 1.33) 0.59
  HPFS 695 1 (ref) 0.88 (0.71, 1.09) 1.00 (0.83, 1.21) 0.71 (0.51, 1.00) 0.10
  Pooled 1 (ref) 0.99 (0.82, 1.19) 0.96 (0.86, 1.07) 0.81 (0.65, 0.99) 0.06
  Lung
  NHS 1,205 1 (ref) 1.00 (0.86, 1.16) 0.92 (0.79, 1.07) 0.87 (0.58, 1.30) 0.26
  HPFS 742 1 (ref) 0.88 (0.72, 1.07) 0.90 (0.75, 1.09) 0.87 (0.63, 1.21) 0.35
  Pooled 1 (ref) 0.96 (0.85, 1.08) 0.91 (0.81, 1.03) 0.87 (0.67, 1.11) 0.15
  Bladder
  NHS 357 1 (ref) 0.95 (0.70, 1.26) 0.96 (0.74, 1.25) 1.33 (0.74, 2.37) 0.54
  HPFS 592 1 (ref) 1.06 (0.85, 1.32) 1.07 (0.87, 1.32) 1.31 (0.94, 1.83) 0.12
  Pooled 1 (ref) 1.00 (0.84, 1.19) 1.02 (0.87, 1.20) 1.32 (0.99, 1.76) 0.09
  Kidney
  NHS 268 1 (ref) 1.37 (1.00, 1.87) 1.15 (0.84, 1.56) 1.20 (0.58, 2.48) 0.52
  HPFS 272 1 (ref) 0.95 (0.69, 1.30) 0.87 (0.64, 1.18) 0.73 (0.42, 1.27) 0.24
  Pooled 1 (ref) 1.15 (0.77, 1.71) 1.02 (0.75, 1.39) 0.90 (0.57, 1.41) 0.85
Abbreviation: CI, confidence interval; HPFS, Health Professionals Follow-up Study; NHS, Nurses’ Health Study All the models were adjusted for 
age (years), ethnicity (European Americans, Asian, African American, other), body mass index (calculated as weight in kilograms divided by 
height in meters squared; < 21.0, 21.0-22.9, 23.0-24.9, 25.0-26.9, 27.0-29.9, 30.0-32.9, 33.0-34.9, or ≥ 35.0), smoking status (never smoked, past 
smokers, current smokers 1-14 cigarettes/day, 15-24 cigarettes/day, or ≥ 25 cigarettes/day), physical activity (MET-hours/week, in quintiles), family 
history of cancer (yes or no), multivitamin supplementation (yes or no), total energy intake (kilocalories/day, in quintiles), consumption of fruit, 
vegetables, red meat, fish, nuts, whole grain (except brown rice), sugar-sweetened beverage (all in quintiles). For women, postmenopausal hormone 
use (yes or no) was further adjusted for.
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